| NCT06555328 | Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa | RECRUITING | PHASE2 | 2025-01-02 | 2025-12 | 2025-12 |
| NCT05964413 | Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum | TERMINATED | PHASE3 | 2023-11-01 | 2025-07-11 | 2025-07-11 |
| NCT04812535 | Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC. | TERMINATED | PHASE2 | 2021-03-31 | 2024-06-04 | 2024-06-04 |
| NCT04333420 | Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia | COMPLETED | PHASE2, PHASE3 | 2020-03-31 | 2021-12-01 | 2021-10-31 |
| NCT03971643 | Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum | COMPLETED | PHASE2 | 2019-05-16 | 2022-01-03 | 2022-01-03 |
| NCT03895801 | Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis. | COMPLETED | PHASE2 | 2019-04-03 | 2021-06-08 | 2021-04-14 |
| NCT03712345 | Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA | TERMINATED | PHASE2 | 2018-10-15 | 2021-05-03 | 2020-09-10 |
| NCT03487276 | Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) | COMPLETED | PHASE2 | 2018-02-26 | 2020-01-27 | 2019-05-27 |
| NCT03001622 | Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa | COMPLETED | PHASE2 | 2016-12 | 2017-07 | 2017-07 |
| NCT02866825 | Studying Complement Inhibition in Complex Cardiac Surgery | COMPLETED | PHASE2 | 2016-05 | 2017-01 | 2016-12 |
| NCT02246595 | Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction | COMPLETED | PHASE2 | 2014-04 | 2015-12 | 2015-12 |
| NCT01319903 | Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29 | COMPLETED | PHASE1 | 2011-03 | 2011-10 | 2011-10 |